Claudia Serrano-Gomez, MD
Interventional Cardiology · New York, NYNPI 1427273762
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by AstraZeneca at 48.0% of the total. Reporting peaked in 2024 at $58,708 and has fallen 67.8% since, to $18,928 in 2025. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 571 payments — averaging $259.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$71K
- Terumo Medical Corporation$26K
- Lexicon Pharmaceuticals, Inc.$22K
- Shockwave Medical, Inc$11K
- Abbott$4K
- Johnson & Johnson$2K
- plus $12K from 28 others
Across 54 payments — averaging $3532.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$125K
- Abbott$35K
- Cardiovascular Systems Inc.$31K
What the payments were for
- Consulting fees$30,85021%
- Speaking & faculty fees$88,78060%
- Travel & lodging$9,3316%
- Food & beverage$19,32013%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 110 | $71,225 |
| Terumo Medical Corporation | 35 | $26,077 |
| Lexicon Pharmaceuticals, Inc. | 42 | $22,103 |
| Shockwave Medical, Inc | 25 | $10,819 |
| Abbott | 65 | $4,158 |
| Johnson & Johnson | 23 | $2,107 |
| Abiomed | 10 | $1,480 |
| Medtronic(2 entities) | 18 | $1,203 |
| Penumbra, Inc. | 5 | $1,197 |
| Spectrawave, Inc | 6 | $1,153 |
| Novartis | 65 | $1,018 |
| E.r. Squibb & Sons, L.L.C. | 40 | $912 |
| Amgen | 40 | $792 |
| Janssen Scientific Affairs, LLC | 8 | $790 |
| Boston Scientific | 5 | $628 |
| Bayer | 15 | $478 |
| Boehringer Ingelheim | 16 | $369 |
| Pfizer | 8 | $287 |
| Novo Nordisk | 5 | $194 |
| Cordis US CORP. | 1 | $189 |
| Cardiovascular Systems Inc. | 4 | $189 |
| Amarin Pharma, Inc. | 7 | $187 |
| Bridgebio Pharma, Inc. | 2 | $135 |
| Teleflex LLC | 1 | $131 |
| ZOLL Circulation Inc | 1 | $121 |
| Alnylam Pharmaceuticals Inc. | 1 | $90 |
| Agepha Pharma FZ LLC | 3 | $74 |
| Scpharmaceuticals Inc. | 3 | $72 |
| Lilly USA, LLC | 2 | $35 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $21 |
| Merck | 1 | $18 |
| GSK | 1 | $15 |
| Biotronik Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$42,212
- FARXIGA$23,252
- Inpefa$21,207
- Optitorque$13,047
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$10,470
- METACROSS OTW$5,897
- BRILINTA$4,638
- GlideWire$2,250
- XARELTO$1,897
- GLIDESHEATH SLENDER$1,861
- ANGIO-SEAL$1,350
- Impella$1,336
- Indigo System$1,167
- HeartMate Touch$1,000
- HyperVue Imaging System$984
- Starlight Imaging Catheter$794
- OPTIS$707
- RESOLUTE ONYX$537
- Xience Sierra Coronary Stent$353
- WAINUA$250
How this compares
$148,301 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 442 | $484,601 |
| EliquisApixaban | 236 | $253,108 |
| JardianceEmpagliflozin | 176 | $233,901 |
| EntrestoSacubitril/Valsartan | 154 | $183,141 |
| XareltoRivaroxaban | 80 | $88,952 |
| VascepaIcosapent Ethyl | 155 | $75,616 |
| BrilintaTicagrelor | 74 | $58,003 |
| KerendiaFinerenone | 33 | $44,584 |
| Repatha SureclickEvolocumab | 30 | $44,264 |
| Praluent PenAlirocumab | 33 | $35,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $16,579 |
| Atorvastatin Calcium | 788 | $10,881 |
| Repatha PushtronexEvolocumab | 13 | $10,541 |
| Valsartan | 277 | $10,356 |
| Metoprolol Succinate | 550 | $8,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $71,225 | $542,604516 claims |
| PfizerEliquis | $287 | $253,108236 claims |
| Boehringer IngelheimJardiance | $369 | $233,901176 claims |
| NovartisEntresto | $1,018 | $183,141154 claims |
| Johnson & JohnsonXarelto | $2,107 | $88,95280 claims |
| BayerKerendia | $478 | $44,58433 claims |
| GSKTrelegy Ellipta | $15 | $16,57927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.